TG Therapeutics GAAP EPS of $0.35 misses by $0.01, revenue of $259.9M beats by $14.45M (TGTX:NASDAQ)
TG Therapeutics (TGTX) reported Q3 GAAP EPS of $0.35, missing estimates by $0.01. Revenue was $259.9M, beating expectations by $14.45M. The company raised its full-year revenue guidance to $1B from $950M, and BRIUMVI U.S. net product revenue guidance to $915-920M from $890-905M. Shares rose 7% post-market.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise have already pushed the stock up 7% pre‑market, indicating immediate trading interest.
Market read
Earnings surprise and guidance lift provide a clear short‑term trading catalyst for TGTX.
What to watch
Potential upcoming competition for BRIUMVI and regulatory risk are not reflected in the price move.
Background
TG Therapeutics reported Q3 2026 results with a slight EPS miss but a solid revenue beat and raised full‑year guidance.
Ticker impact
Q3 GAAP EPS of $0.35 missed by $0.01, revenue beat to $259.9M and full-year 2026 revenue guidance raised to ~$1B, shares up 7% pre‑market.
likely upward pressure as market prices in the revenue beat and higher guidance
Earnings beat and guidance lift are fresh, material, and already moved the stock +7% pre‑market.
Market effects
Biotech sector may see modest uplift as a peer demonstrates strong product revenue growth.
U.S. biotech stocks could benefit from the positive earnings surprise.
Limited to investors focused on U.S. biotech and specialty pharma.
Counterpoint
The EPS miss, albeit small, could signal margin pressure if revenue growth slows.
Key entities
- companyTG Therapeutics, Inc.
Biopharmaceutical company focused on BRIUMVI and other oncology products.
